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Abstract Despite the use of radiation and chemotherapy,
the prognosis for children with diffuse brainstem gliomas is
extremely poor. There is a need for relevant brainstem
tumor models that can be used to test new therapeutic
agents and delivery systems in pre-clinical studies. We
report the development of a brainstem-tumor model in rats
and the application of bioluminescence imaging (BLI) for
monitoring tumor growth and response to therapy as part of
this model. Luciferase-modiﬁed human glioblastoma cells
from ﬁve different tumor cell sources (either cell lines or
serially-passaged xenografts) were implanted into the
pontine tegmentum of athymic rats using an implantable
guide-screw system. Tumor growth was monitored by BLI
and tumor volume was calculated by three-dimensional
measurements from serial histopathologic sections. To
evaluate if this model would allow detection of therapeutic
response, rats bearing brainstem U-87 MG or GS2 glio-
blastoma xenografts were treated with the DNA methy-
lating agent temozolomide (TMZ). For each of the tumor
cell sources tested, BLI monitoring revealed progressive
tumor growth in all animals, and symptoms caused by
tumor burden were evident 26–29 days after implantation
of U-87 MG, U-251 MG, GBM6, and GBM14 cells, and
37–47 days after implantation of GS2 cells. Histopatho-
logic analysis revealed tumor growth within the pons in all
rats and BLI correlated quantitatively with tumor volume.
Variable inﬁltration was evident among the different
tumors, with GS2 tumor cells exhibiting the greatest degree
of inﬁltration. TMZ treatment groups were included for
experiments involving U-87 MG and GS2 cells, and in
each case TMZ delayed tumor growth, as indicated by BLI
monitoring, and signiﬁcantly extended survival of animal
subjects. Our results demonstrate the development of a
brainstem tumor model in athymic rats, in which tumor
growth and response to therapy can be accurately moni-
tored by BLI. This model is well suited for pre-clinical
testing of therapeutics that are being considered for treat-
ment of patients with brainstem tumors.
Keywords Brainstem tumor  Animal model 
Bioluminescence  Temozolomide
Introduction
Brainstem gliomas represent 10–15% of brain tumors in
children and show varying degrees of malignancy [1]. The
majority of brainstem gliomas are diffuse pontine tumors
and patients with these tumors rarely survive beyond
2 years from initial diagnosis [1]. Factors that contribute to
the dismal prognosis associated with diffuse pontine glio-
mas include inﬁltrative nature and anatomic location in an
eloquent area of the brain which precludes surgical resec-
tion [1, 2]. Although many radiation and chemotherapy
regimens have been used to treat diffuse pontine gliomas,
the long-term outcome has not changed substantially [1, 2].
Recent advances in the treatment of high-grade supra-
tentorial gliomas in adults have led to the development of
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DOI 10.1007/s11060-009-9954-9more potent and speciﬁc anticancer agents and new drug
delivery systems [2–6]. Undoubtedly, the translation
of these new therapies and approaches to the treatment of
diffuse pontine gliomas would be facilitated through use of
an animal model designed speciﬁcally for preclinical
therapeutic testing. The model that best mimic the human
clinical condition involves transplantation of human gli-
oma cells that have been well-characterized in their
response to chemotherapeutic agents and ionizing radiation
[7–10].
When using intracranial xenograft models, therapeutic
efﬁcacy is usually measured by the time required for ani-
mals to develop symptoms associated with tumor burden.
An alternative approach for assessing intracranial xeno-
graft response to therapy is bioluminescence imaging
(BLI), which detects photon emissions associate with an
ATP-dependent process catalyzed by metabolically active
cells that express a luciferase reporter gene. BLI has been
shown to allow noninvasive, quantitative, and real-time
monitoring of tumor growth and response to therapy in
many small-animal models [11–16].
Here, we report the development and application of an
orthotopic brainstem tumor model in athymic rats using a
guide-screw system to implant human glioblastoma cells,
and that is followed by BLI monitoring. In association with
this model system, BLI accurately reﬂects orthotopic tumor
growth and is able to measure tumor response to the DNA
methylating agent temozolomide (TMZ). Our model sys-
tem with adaptation for BLI should prove useful for pre-
clinical testing of therapeutics for treating patients with
brainstem tumors.
Materials and methods
Cell culture
U-87 MG and U-251 MG human glioblastoma cells were
obtained from the Department of Neurological Surgery
Tissue Bank at the University of California, San Fran-
cisco (UCSF), and were propagated as exponentially
growing monolayers in complete medium consisting of
Eagle’s minimal essential medium supplemented with
10% fetal bovine serum and non-essential amino acids.
The GS2 cell line was obtained from Manfred Westphal,
Department of Neurological Surgery, University Hospital
Eppendorf, Hamburg, Germany, and maintained as a
neurosphere culture, as previously described [17]. GBM6
and GBM14 cells were obtained from C. David James,
Department of Neurological Surgery, UCSF, and propa-
gated as subcutaneous xenografts that were harvested and
prepared for intracranial injection, as previously described
[18].
Modiﬁcation of tumor cells with ﬁreﬂy-luciferase-
expressing reporter
U-87 MG, U-251 MG, GBM6, GBM14, and GS2 cells
were transduced with a lentiviral vector containing ﬁreﬂy
luciferase (Fluc) under the control of the spleen focus
forming virus (SFFV) promoter. Lentiviral vectors were
generated by transfection of 293T (human embryonal
kidney) cells with plasmids encoding the vesicular stoma-
titis virus G envelope, gag-pol, and Fluc genes [16, 19].
Viral vectors were harvested from supernatant 48 hours
after transfection, ﬁltered, and then used to infect glio-
blastoma cells. Cells were screened for transfection efﬁ-
ciency by treatment with luciferin (D-luciferin potassium
salt, 150 mg/kg, Gold Biotechnology, St Louis, MO) in
vitro and examination by a Xenogen IVIS Lumina System
(Xenogen Corp., Alameda, CA). More than 80% of cells
were transfected.
Animals
Six-week-old male athymic rats (rnu/rnu, homozygous)
were purchased from the National Cancer Institute (Fred-
erick, MD). Rats were housed in an animal facility and
were maintained in a temperature-controlled and light-
controlled environment with an alternating 12-hour light/
dark cycle. All protocols were approved by the UCSF
Institutional Animal Care and Use Committee.
Surgical procedure for implantation of tumor cells
Before injecting tumor cells into the brainstem, rats were
anesthetized by intraperitoneal injection of 75 mg/kg of
ketamine and 7.5 mg/kg of xylazine. Anesthetized rats
were then positioned in a stereotactic device (David Kopf
Instruments, Tujunga, CA) using ear bars. A burr hole was
drilled through the skull 1.0 mm behind the lambda, and
9.6 mm deep from the inner surface of the skull. 1 9 10
5
tumor cells suspended in 1 ll HBSS were injected slowly
(over 1 minute) into the pontine tegmentum using a guide-
screw system. All procedures were carried out under sterile
conditions.
In vivo BLI monitoring
In vivo BLI was performed with the Xenogen IVIS Lumina
System coupled LivingImage software for data acquisition
(Xenogen Corp.). Rats were anesthetized with 75 mg/kg of
ketamine and 7.5 mg/kg of xylazine and imaged 12 min
after intraperitoneal injection of luciferin. Signal intensity
was quantiﬁed within a region of interest over the head that
was deﬁned by the LivingImage software. There was
considerable variation in luminescence among tumor-
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123bearing mice. To facilitate comparison of growth rates,
each mouse’s luminescence readings were normalized
against its own luminescence reading at day 14 (last BLI
before initiation of therapy), thereby allowing each mouse
to serve as its own control [14].
Growth kinetics of brainstem tumor xenografts
Eight rats were injected with 1 9 10
5 luciferase-modiﬁed
U-87 MG cells into the brainstem and intratumoral
luciferase activity was monitored by BLI. BLI was per-
formed twice a week beginning 3 days after tumor cells
implantation. Two rats each were euthanized at days 10,
15, 20 and 25 following implantation and immediately
after BLI. Brains were ﬁxed in 10% buffered formalin
and embedded in parafﬁn, sectioned at 250 lm intervals,
and then stained with hematoxillin-eosin (H&E). For the
volumetric assessment of intracranial tumor, tumor
regions were identiﬁed on serially-sectioned H&E stained
slides and digital images of these slides were acquired
and organized as volume wrapper ﬁles, in which images
were in spatial registration. Analyze 7.0 software (Ana-
lyzeDirect, Inc., Overland Park, KS) was used to deter-
mine three-dimensional tumor volumes for each set of
spatially registered images as a function of pixel
dimensions. Estimated relative volumes were compared
with corresponding optical imaging measurements to
determine the extent of correlation between the two
measurements.
Treatment of brainstem tumors in athymic rats with
TMZ
To evaluate the therapeutic response of brainstem tumor
xenografts, rats receiving brainstem injections of lucifer-
ase-modiﬁed U-87 MG or GS2 cells were randomly
assigned to vehicle control (Ora-Plus, Paddock Laborato-
ries, Inc., North Minneapolis, MN) or TMZ treatment
(Temodar, Schering corp., Kenilworth, NJ) groups. For
U-87 MG brainstem xenografts, the treatment group
received daily dose of 50 mg/kg of TMZ by oral gavage for
5 consecutive. Treatment was initiated on day 15 when
brainstem tumors had achieved a log growth phase, as
indicated by BLI monitoring. For GS2 brainstem xeno-
grafts, the treatment group received a single dose of
100 mg/kg TMZ by oral gavage on day 28. All rats were
monitored every day for the development of symptoms
related to tumor growth and twice weekly by BLI. Mean
BLI values for control and treatment groups were calcu-
lated and plotted according to the corresponding day of
imaging. Rats were euthanized when they exhibited
symptoms indicative of signiﬁcant compromise to neuro-
logical function.
TUNEL staining
To determine if TMZ caused an apoptotic response in
tumor cells, the brains from one control and one TMZ-
treated rat were resected immediately following comple-
tion of the treatment regimen at day 5, placed in formalin
A U-87 MG
Day 20 Day 24 Day 20
B
U-251 MG GBM 6
Day 25
GBM 14
Day 44
GS2
GS2
Fig. 1 Comparison of tumor
morphology associated with
different GBM cell lines
following implantation into the
rodent pons. a 1 9 10
5
luciferase-modiﬁed U-87 MG,
U-251 MG, GBM6, GBM 14,
and GS2 glioblastoma cells
were injected into brainstem in
athymic rats using an
implantable guide-screw
system. b GS2 cells showed the
greatest degree of inﬁltration
within the pons, but show a
lesser extent of inﬁltration than
is evident following
supratentorial injection in
athymic mice
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123and embedded in parafﬁn. The parafﬁn-embedded sections
were assessed for apoptosis using terminal nucleotidyl
transferase-mediated nick end labeling (TUNEL) staining.
TUNEL staining was performed using the ApopTag
Peroxidase In situ Apoptosis detection kit (CHEMICON,
Temecula, CA), according to the manufacturer’s instruc-
tion. Counterstaining was performed using hematoxillin.
The number of TUNEL-positive cells was counted in four
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Fig. 2 Association between
bioluminescence signal and
corresponding tumor volume in
rats receiving brainstem
injection of U-87 MG cells.
a Eight rats were injected with
luciferase-modiﬁed U-87 MG
glioblastoma cells and
bioluminescence monitoring
was performed twice a week,
beginning 3 days after tumor
cell implantation. Two rats each
were euthanized on days 10, 15,
20, and 25 following BLI.
Histopathologic analysis reveals
progressive U-87 MG tumor
growth from day 10 to 25
(arrows,2 9 magniﬁcation).
b Bioluminescence imaging
(BLI) shows a corresponding
signal increase from the tumors.
c Brains from rats euthanized at
days 10, 15, 20 and 25 after
U-87 MG tumor cells
implantation were serially
sectioned at 250 lm intervals.
Tumor size from digital images
of serially-registered sections
were compared with
corresponding BLI
measurements to determine the
extent of correlation.
Quantitative comparison of
relative tumor volume with
corresponding luminescence
values (R
2 = 0.9467)
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123high-power ﬁelds (200 9 magniﬁcation) from each rat,
and mean values determined.
Statistical analysis
The Kaplan–Meier estimator was used to generate survival
curves, and differences between survival curves were cal-
culated using a log-rank test.
Results
Progressive growth of brainstem xenografts measured
by BLI
Injection of luciferase-modiﬁed U-87 MG, U-251 MG,
GBM6, GBM14, and GS2 human glioblastoma cells into
athymic rats resulted in 100% tumor take (Figs. 1, 2). No
animals suffered adverse effects from the direct brainstem
injection procedure. All animals developed typical poster-
ior fossa symptoms, such as torticollis and nystagmus.
Survival of rats, as determined by criteria necessitating
euthanasia, ranged from 26 to 29 days after implantation of
U-87 MG, U-251 MG, GBM6, and GBM14 cells, and 37 to
47 days after implantation of GS2 cells. Histopathologic
analysis revealed large tumors within the pons in all rats
(Fig. 1a) and corresponding BLI revealed readily detect-
able and quantiﬁable signal from the tumors. Although
most of the cell lines showed a relatively well-circum-
scribed pattern of growth, GS2 cells inﬁltrated more widely
through the pons with a pattern that more closely resembles
the human disease (Fig. 1b, Table 1).
In a time course study involving tumor monitoring by
BLI, rats were injected with luciferase-modiﬁed U-87 MG
cells and euthanized at selected time points following
implantation. Small tumors were detected on day 10 with
increasing tumor size up to day 25. On day 25, solid tumor
was evident in the right pons with extension over the brain
surface (Fig. 2a). BLI revealed increasing signal intensity
corresponding to increasing tumor volume in all animals
(Fig. 2a, b). Implanted tumor cells achieved a logarithmic
growth subsequent to day 10 following implantation, at
which time injected rodents were asymptomatic.
Correlation between bioluminescence and
corresponding tumor volume
H&E stained sections of each tumor bearing brain, from
the time course study, were serially registered and used to
estimate tumor volume. Tumor volumes were compared
with corresponding luminescence signals obtained from
rats immediately prior to euthanasia. There was signiﬁcant
correlation between tumor volume and luminescence sig-
naling (R
2 = 0.9467; Fig. 2c).
Brainstem tumor response to TMZ treatment
To evaluate the therapeutic response of brainstem tumor
xenografts, we used BLI monitoring to measure tumor
response to TMZ in both U-87 MG and GS2 cells. The
normalized luminescence plot for the control group showed
progressively increasing luminescence until rats developed
neurological symptoms indicative of a moribund condition
(Figs. 3, 4). In comparison to the control group rodents
with U-87 MG tumors, luminescence in rats receiving
TMZ treatment was substantially reduced at day 19, when
the treatment was completed, and remained low until day
42 following implantation (Fig. 3b). Survival analysis
revealed that the median survival of rats treated with TMZ
was signiﬁcantly extended relative to controls (53.5 days
vs. 27 days, P = 0.0033; Fig. 3a). To evaluate whether
TMZ caused apoptosis of U-87 MG tumor cells, TUNEL
staining was used to examine tumor tissue from one control
and one treated rat that were sacriﬁced at the completion of
TMZ treatment. Increased numbers of TUNEL-positive
cells were present in the U-87 MG tumor following TMZ
treatment (mean value = 26 TMZ treated vs. 0.75 control,
Fig. 3c).
In rodents with GS2 tumors, TMZ treatment resulted in
complete loss of detectable luminescence (Fig. 4a), and
TMZ treated animals were sacriﬁced at day 72 (Fig. 4b),
with subsequent histopathologic analysis yielding no indi-
cation of tumor in the brains of treated mice (data not
Table 1 Description of glioblastoma cell lines used to establish brainstem tumors
Cell line Propagation method Growth pattern Median survival (days)
U-87 MG Monolayer cell culture with serum Well-circumscribed 28
U-251 MG Monolayer cell culture with serum Inﬁltrative 26
GBM6 Subcutaneous tumor in mouse Inﬁltrative 29
GBM14 Subcutaneous tumor in mouse Circumscribed 28
GS2 Neurosphere cell culture with EGF, FGF, N2, B27 Extensive invasion at tumor margin 44
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Fig. 3 Bioluminescence
monitoring of U-87 MG
brainstem tumor xenografts
treated with TMZ. a U-87 MG
tumor bearing rats were treated
with a daily dose of 50 mg/kg of
TMZ or control vehicle
delivered by oral gavage for 5
consecutive days beginning on
day 15. Bioluminescence
measurements for each rat were
normalized against
corresponding readings obtained
at the beginning of therapy.
TMZ treatment group (n = 4,
white circle) shows a decreased
normalized luminescence value
through day 42, in contrast to
the increasing luminescence
value of control group, that was
ﬁrst evident at day 19 imaging
(n = 5, black circle). b TMZ
treatment signiﬁcantly
prolonged median survival
(P = 0.0033) from 27 days in
the control group (n = 5, black
circle) to 53.5 days in the TMZ
treatment group (n = 4, white
circle). c TUNEL staining
reveals an increase in the
number of TUNEL-positive
cells in tumor from the rat
treated with TMZ, as compared
with the tumor from the control
animal (1009 magniﬁcation;
mean value = 26 vs. 0.75)
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Fig. 4 Bioluminescence
monitoring of GS2 brainstem
tumor xenografts treated with
TMZ. a GS2 tumor bearing rats
were treated with a single dose
of 100 mg/kg of TMZ or control
vehicle delivered by oral gavage
on day 28. Bioluminescence
measurements for each rat were
normalized against
corresponding readings obtained
at the beginning of therapy.
TMZ treatment group (n = 4,
white circle) shows decreasing
normalized luminescence until
no signal is evident in treated
mice, whereas control group
mice show steadily increased
luminescence from day 26
onward (n = 5, black circle).
b TMZ treatment signiﬁcantly
prolonged median survival
(P\0.0001) from 44 days in
the control group (n = 4, black
circle)t o[72 days in the TMZ
treatment group (n = 4, white
circle), at which time all TMZ
treatment group rats were
sacriﬁced and determined as
being devoid of viable tumor
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123shown). All control animals with GS2 tumors required
sacriﬁced by day 47, with large pontine tumors present.
Discussion
In this study, we demonstrate the development of a xeno-
graft model for brainstem glioma that has been adapted to
facilitate pre-clinical testing of new therapies for the
treatment of this cancer. The injection of luciferase-modi-
ﬁed human glioblastoma cells in athymic rats produces
brainstem tumors with a consistent rate of growth, and
permits the use of BLI to quantitatively measure extent and
duration of tumor response to therapy. For animal subjects
receiving injection of tumor cells, histopathologic analysis
revealed that tumor growth is primarily restricted to the
pons, and as such, our approach results in an anatomically
accurate modeling for this type of brain tumor.
Other brainstem tumor models using 9L and F98 rat
glioma cell lines have been reported [20–24]. A potential
limitation of rodent tumor-derived systems is that the
response of rodent cell lines to treatment with anti-cancer
agents can differ from that of human glioma cells [25–27].
Human glioma cell lines offer a distinct advantage with
regard to this concern [7–9].
AmongtheﬁvehumanGBMcelltypesusedinthecurrent
study, we observed variable patterns of growth within the
brainstem. U-87 MG and U-251 MG grew as well-deﬁned
tumors with sharply demarcated margins that do not reca-
pitulate the observed pattern of pontine glioma growth in
humans. Glioblastoma xenograft cell lines (GBM6,
GBM14), and the glioblastoma neurosphere cell line GS2,
all showed a greater extent of inﬁltration relative to U-87
MGandU-251MG,butdemonstratedlesserinﬁltrationthan
has been observed following their supratentorial injection
and growth in athymic mice (Fig. 1b). This may be due to
the greater compaction of white matter pathways in the pons
as compared to the cerebral hemispheres.
A reﬁnement of our brainstem xenograft model is the
use of BLI, which is a cost-effective, efﬁcient, and accurate
means for assessing tumor growth and response to therapy.
In our time course study following injection of U-87 MG
cells, bioluminescence signal was readily detectable on day
10 following tumor cell implantation, and well in advance
of animals developing neurological symptoms. With
respect to therapy response, the anti-tumor effect of TMZ
treatment was readily detected by BLI, and the BLI effects
of treatment foreshadowed corresponding increases in
animal survival. These ﬁndings suggest that BLI can be
used as an accurate surrogate to survival for assessing
effect of therapy. One limitation of BLI is that metabolism
of luciferin and photon emission can occur in non-dividing
cells that are still viable. Therefore, loss of luminescent
signal may not always correlate with tumor cell killing. It
should also be noted that the sensitivity of U-87 MG and
GS2 cells to TMZ is known and this drug was selected
primarily to test the effectiveness of the model system
rather than screen a potential therapeutic agent. In fact,
clinical trials have not shown a meaningful response to
TMZ in the treatment of pontine gliomas in children [28].
In the current era, most diffusely inﬁltrating brainstem
gliomas are treated without a surgical biopsy [1]. The
corresponding lack of tissue samples has resulted in a
limited understanding of the underlying genetic and bio-
chemical abnormalities associated with these tumors [29],
and may explain why chemotherapeutic agents that have
shown efﬁcacy in other brain tumors have not been espe-
cially effective in clinical trials for brainstem gliomas. This
limitation is of some concern for the model we present
here, since all tumor cell sources we have used were
obtained from adult GBM. A ﬁnal limitation is that
immunotherapy approaches cannot be effectively tested in
immunodeﬁcient animals. Nonetheless, this model is ana-
tomically acccurate, allows ongoing quantitative assess-
ment of tumor response, and can be easily adapted to
establish a biologically faithful model if an adequate tissue
specimen from a brainstem glioma becomes available in
the future. In total, our approach, in which appropriate
anatomic modeling is combined with BLI monitoring,
should greatly enhance the testing of new therapeutics, as
well as testing new strategies to deliver therapeutic agents,
such as convection-enhanced delivery [2–4].
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